BRIEF-Arcus Biosciences Says Dosed First Subject In ARC-10
BRIEF-Arcus Biosciences Says Dosed First Subject In ARC-10
* ARCUS BIOSCIENCES INC - HAS DOSED FIRST SUBJECT IN ARC-10, A PHASE 3 STUDY
* ARCUS BIOSCIENCES - DOSING OF FIRST SUBJECT TRIGGERS MILESTONE PAYMENTS TO WUXI BIOLOGICS OF $10 MILLION AND ABMUNO THERAPEUTICS OF $5 MILLION
* ARCUS BIOSCIENCES INC - WILL OWE A SUBSEQUENT MILESTONE PAYMENT UPON INITIATION OF A PHASE 3 TRIAL IN A SECOND INDICATION
Source text: () Further company coverage:
((Reuters.Briefs@thomsonreuters.com;)
March 16 (Reuters) - Arcus Biosciences Inc :
* ARCUS BIOSCIENCES INC - HAS DOSED FIRST SUBJECT IN ARC-10, A PHASE 3 STUDY
* ARCUS BIOSCIENCES - DOSING OF FIRST SUBJECT TRIGGERS MILESTONE PAYMENTS TO WUXI BIOLOGICS OF $10 MILLION AND ABMUNO THERAPEUTICS OF $5 MILLION
* ARCUS BIOSCIENCES INC - WILL OWE A SUBSEQUENT MILESTONE PAYMENT UPON INITIATION OF A PHASE 3 TRIAL IN A SECOND INDICATION
Source text: () Further company coverage:
((Reuters.Briefs@thomsonreuters.com;)
路透3月16日電-Arcus Biosciences Inc：*Arcus Biosciences Inc-已經在ARC-10中給第一個受試者劑量，這是一項第三階段的研究*Arcus Biosciences-第一個受試者的劑量觸發向藥明生物和ABMUNO治療公司分別支付1,000萬美元和500萬美元的里程碑式付款*Arcus Biosciences Inc-在第二個適應症中啟動3期試驗後，將欠下一筆里程碑式的付款源文本：()進一步的公司報道：(Reurs.Briefs@thomsonreurs.com；)
譯文內容由第三人軟體翻譯。
風險及免責聲明
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧